@gregoryogallagher's tirzepatide claims, fact-checked

What did @gregoryogallagher actually say?

Honestly? Not much that can be fact-checked. The transcript captured here reads as fragmented, possibly song lyrics or a voiceover: "I forgot to look at you in time when I eat you / It's the game I'll smile so long." The caption says "Tirzeppy baby," which is a street-slang nickname for tirzepatide (Mounjaro/Zepbound). So the video is almost certainly about tirzepatide, but the spoken content gives us almost nothing to analyze medically.

This is a pattern on TikTok: a creator posts a trending drug reference with a catchy caption, lets the hashtag do the work, and the actual medical claims live in the implication rather than the script. The peptide category tag here lumps tirzepatide in with research peptides like BPC-157 and ipamorelin, which is itself worth scrutinizing. Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist. It is not a research peptide in the same regulatory or pharmacological sense.

Does the science back this up?

Tirzepatide has a genuinely strong evidence base, which is more than can be said for most things trending on peptide TikTok. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed up to 22.5% mean body weight reduction in adults with obesity over 72 weeks. That is a real, peer-reviewed, phase 3 number.

What the science does not support is the casual framing of tirzepatide as just another peptide optimization tool in the same bucket as MK-677 or CJC-1295. Those compounds have sparse human trial data, no FDA approval, and significant unknown risk profiles. Tirzepatide has a known adverse event profile including nausea, vomiting, gastroparesis risk, and potential thyroid C-cell concerns flagged in animal studies. Treating it like a biohacker peptide stack glosses over the fact that this is a regulated pharmaceutical with real contraindications and a prescribing infrastructure for a reason.

• SURMOUNT-1: 2539 participants, 72 weeks, up to 22.5% weight loss (Jastreboff et al., 2022, NEJM)
• SURPASS trials confirmed HbA1c reduction and cardiovascular risk factor improvement in T2D populations
• FDA approved tirzepatide (Mounjaro) for T2D in May 2022, Zepbound for obesity in November 2023

What did they get wrong (or right)?

Without concrete spoken claims, we are largely fact-checking the framing. Getting it right: tirzepatide is genuinely effective, and public awareness of GLP-1 class drugs is not inherently harmful. Getting it wrong: categorizing tirzepatide under "peptide therapy" alongside research compounds creates a false equivalency that could lead viewers to treat a prescription drug as casually acquirable.

The nickname "Tirzeppy" is harmless slang, but the context matters. Compounded tirzepatide has been a significant regulatory flashpoint. The FDA placed semaglutide and tirzepatide on its shortage list, which temporarily allowed compounding pharmacies to produce copies. That status has shifted, and the FDA has issued warnings about compounded versions not being the same as FDA-approved products. Framing tirzepatide as a fun peptide hack, without any of that context, is irresponsible even if nothing explicitly false is stated.

The peptide category tag is also doing real damage here. Viewers searching for BPC-157 recovery protocols will land on tirzepatide content without any scaffolding about the difference in regulatory status, mechanism, or risk profile.

What should you actually know?

Tirzepatide works through a dual mechanism that older GLP-1 drugs do not have. It activates both GLP-1 and GIP receptors, which appears to produce additive effects on satiety, insulin secretion, and possibly energy expenditure. This is not the same as peptides like ipamorelin or CJC-1295, which work on growth hormone secretagogue pathways.

If you are considering tirzepatide, the conversation belongs with a licensed prescriber, not a TikTok comment section. Side effects are real and can be serious: pancreatitis, gallbladder disease, and potential thyroid tumors in rodent studies (clinical significance in humans is still being evaluated). It also requires ongoing use to maintain results. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed significant weight regain after discontinuation.

The compounding question is also live. The FDA has declared the tirzepatide shortage resolved, meaning compounded versions are no longer automatically permissible under shortage exemptions. Anyone sourcing compounded tirzepatide outside a supervised clinical setting is operating in legally and medically uncertain territory right now.